Indian CRISPR diagnostics startup CrisprBits closed a $3 million pre‑Series A round led by Spectrum Impact to expand CRISPR‑based diagnostics and R&D capabilities. The financing aims to accelerate productization of point‑of‑care assays and scale lab operations. In parallel, Myrio Therapeutics announced a technical milestone: binders engineered to increase both affinity and specificity, a claim that could influence discovery platforms and biologics screening. The dual news illustrates steady, selective capital flows into platform and diagnostic start‑ups despite broader market caution.